Reply to “Minor Contribution of UGT1A1 Inhibition to Atazanavir-Related Bilirubin Elevation Supported by Conservative PBPK Modeling and Clinical Data”

John O. Miners; Thomas M. Polasek

doi:10.1002/cpt.70184

Reply to “Minor Contribution of UGT1A1 Inhibition to Atazanavir-Related Bilirubin Elevation Supported by Conservative PBPK Modeling and Clinical Data”

John O. Miners
, Thomas M. Polasek

College of Medicine and Public Health

Research output: Contribution to journal › Letter › peer-review

Abstract

We thank Dong and colleagues for their response to our Commentary,1 and for providing greater clarity regarding their PBPK simulations of the bilirubin – atazanavir interaction.

Original language	English
Pages (from-to)	587
Number of pages	1
Journal	Clinical Pharmacology and Therapeutics
Volume	119
Issue number	3
Early online date	21 Dec 2025
DOIs	https://doi.org/10.1002/cpt.70184
Publication status	Published - Mar 2026

Keywords

UGT1A1
PBPK modelling
bilirubin
Atazanavir
OATP1B1
hepatocellular

Access to Document

10.1002/cpt.70184Licence: In Copyright

Cite this

@article{01c52faa3e874660b1c95c983164383e,

title = "Reply to “Minor Contribution of UGT1A1 Inhibition to Atazanavir-Related Bilirubin Elevation Supported by Conservative PBPK Modeling and Clinical Data”",

abstract = "We thank Dong and colleagues for their response to our Commentary,1 and for providing greater clarity regarding their PBPK simulations of the bilirubin – atazanavir interaction.",

keywords = "UGT1A1, PBPK modelling, bilirubin, Atazanavir, OATP1B1, hepatocellular",

author = "Miners, \{John O.\} and Polasek, \{Thomas M.\}",

year = "2026",

month = mar,

doi = "10.1002/cpt.70184",

language = "English",

volume = "119",

pages = "587",

journal = "Clinical Pharmacology and Therapeutics",

issn = "0009-9236",

publisher = "Wiley-Blackwell",

number = "3",

}

TY - JOUR

T1 - Reply to “Minor Contribution of UGT1A1 Inhibition to Atazanavir-Related Bilirubin Elevation Supported by Conservative PBPK Modeling and Clinical Data”

AU - Miners, John O.

AU - Polasek, Thomas M.

PY - 2026/3

Y1 - 2026/3

N2 - We thank Dong and colleagues for their response to our Commentary,1 and for providing greater clarity regarding their PBPK simulations of the bilirubin – atazanavir interaction.

AB - We thank Dong and colleagues for their response to our Commentary,1 and for providing greater clarity regarding their PBPK simulations of the bilirubin – atazanavir interaction.

KW - UGT1A1

KW - PBPK modelling

KW - bilirubin

KW - Atazanavir

KW - OATP1B1

KW - hepatocellular

UR - https://www.scopus.com/pages/publications/105025572593

U2 - 10.1002/cpt.70184

DO - 10.1002/cpt.70184

M3 - Letter

C2 - 41423843

AN - SCOPUS:105025572593

SN - 0009-9236

VL - 119

SP - 587

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

IS - 3

ER -

Reply to “Minor Contribution of UGT1A1 Inhibition to Atazanavir-Related Bilirubin Elevation Supported by Conservative PBPK Modeling and Clinical Data”

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this